These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 29291023)

  • 41. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
    Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment.
    Li Z; Wang J; Ge SS; Qiu QC; Du JH; Shan SS; Shen XD; Wan CL; Wang BR; Wu DP; Qiu HY; Xue SL
    Front Oncol; 2022; 12():841276. PubMed ID: 35211416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.
    Zhou W; Xu J; Gelston E; Wu X; Zou Z; Wang B; Zeng Y; Wang H; Liu A; Xu L; Liu Q
    Oncotarget; 2015 Aug; 6(25):21557-71. PubMed ID: 26188358
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA.
    Fairchild CK; Floros KV; Jacob S; Coon CM; Puchalapalli M; Hu B; Harada H; Dozmorov MG; Koblinski JE; Smith SC; Domson G; Leverson JD; Souers AJ; Takebe N; Ebi H; Faber AC; Boikos SA
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34065859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma.
    Tanos R; Karmali D; Nalluri S; Goldsmith KC
    BMC Cancer; 2016 Feb; 16():97. PubMed ID: 26874859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
    Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A concise review of BCL-2 inhibition in acute myeloid leukemia.
    Yogarajah M; Stone RM
    Expert Rev Hematol; 2018 Feb; 11(2):145-154. PubMed ID: 29264938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
    Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
    Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [New therapeutic agents for acute myeloid leukemia].
    Hosono N
    Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
    Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
    Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pan-Bcl2 Inhibitor AT101 Activates the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells.
    Zhang L; Zhou Y; Chen K; Shi P; Li Y; Deng M; Jiang Z; Wang X; Li P; Xu B
    Target Oncol; 2017 Oct; 12(5):677-687. PubMed ID: 28710745
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
    Jiang J; Wang Y; Liu D; Wang X; Zhu Y; Tong J; Chen E; Xue L; Zhao N; Liang T; Zheng C
    Immunotargets Ther; 2023; 12():135-147. PubMed ID: 38026089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
    Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
    Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.
    Tibes R; Bogenberger JM
    Front Oncol; 2019; 9():1205. PubMed ID: 31921615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mechanisms of resistance to venetoclax in hematologic malignancies.
    Zielonka K; Jamroziak K
    Adv Clin Exp Med; 2024 Mar; ():. PubMed ID: 38439610
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
    Yamauchi T
    Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Vereertbrugghen A; Colado A; Gargiulo E; Bezares RF; Fernández Grecco H; Cordini G; Custidiano MDR; François JH; Berchem G; Borge M; Paggetti J; Moussay E; Gamberale R; Giordano M; Morande PE
    Front Oncol; 2021; 11():598319. PubMed ID: 34381700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.